



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/238267/2023

## European Medicines Agency decision P/0239/2023

of 14 June 2023

on the granting of a product specific waiver for belzutifan, (EMA-002619-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**



# European Medicines Agency decision

P/0239/2023

of 14 June 2023

on the granting of a product specific waiver for belzutifan, (EMA-002619-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Merck, Sharp & Dohme (Europe) Inc on 20 January 2023 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 April 2023 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

## **Article 1**

A waiver for belzutifan, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

## **Article 2**

This decision is addressed to Merck, Sharp & Dohme (Europe) Inc, 5 Clos du Lynx, 12000 – Brussels, Belgium.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/91167/2023  
Amsterdam, 26 April 2023

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-002619-PIP02-23

### Scope of the application

#### Active substance(s):

Belzutifan

#### Invented name and authorisation status:

See Annex II

#### Condition(s):

Treatment of von Hippel-Lindau disease (except von Hippel-Lindau disease- associated renal cell carcinoma)

Treatment of neuroendocrine tumours (except neuroblastoma)

#### Pharmaceutical form(s):

Tablet

#### Route(s) of administration:

Oral use

#### Name/corporate name of the PIP applicant:

Merck, Sharp & Dohme (Europe) Inc

### Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Merck, Sharp & Dohme (Europe) Inc submitted to the European Medicines Agency on 20 January 2023 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.



## Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and all the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

**Annex I**

**Grounds for the granting of the waiver**

# 1. Waiver

## **1.1. Condition:**

Treatment of von Hippel-Lindau disease (except von Hippel-Lindau disease- associated renal cell carcinoma)

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

## **1.2. Condition:**

Treatment of neuroendocrine tumours (except neuroblastoma)

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- tablet, oral use,
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

## **Annex II**

### **Information about the authorised medicinal product**

***Information provided by the applicant:***

**The product is not authorised anywhere in the European Community.**